Inferra AI / Company / STAA
Staar Surgical CO
STAA · Health Care
Last earnings Aug 12, 2026
Key results
Y net incomequarter
$5.2 million
Y Net Income of $5.2 million, with GAAP EPS of $0.10 Adjusted EBITDA 1 of $24.4 million, or $0.48 per diluted share Earnings Call and Webcast Today at
SEC original ↗Staar Surgical CO — Earnings release (8-K exhibit)EX-99May 13, 2026
EPSquarter
$0.10
Y Net Income of $5.2 million, with GAAP EPS of $0.10 Adjusted EBITDA 1 of $24.4 million, or $0.48 per diluted share Earnings Call and Webcast Today at
SEC original ↗Staar Surgical CO — Earnings release (8-K exhibit)EX-99May 13, 2026
Net revenuequarter
$93.5 million
First Quarter 2026 Financial Overview • Net sales of $93.5 million, up 119.6% Y/Y • Net sales excluding China of $46.1 million, up 6.0% Y/Y • Gross margin at 73.6% vs.
SEC original ↗Staar Surgical CO — Earnings release (8-K exhibit)EX-99May 13, 2026
Growthquarter
up 119.6%
First Quarter 2026 Financial Overview • Net sales of $93.5 million, up 119.6% Y/Y • Net sales excluding China of $46.1 million, up 6.0% Y/Y • Gross margin at 73.6% vs.
SEC original ↗Staar Surgical CO — Earnings release (8-K exhibit)EX-99May 13, 2026
Gross marginquarter
73.6%
First Quarter 2026 Financial Overview • Net sales of $93.5 million, up 119.6% Y/Y • Net sales excluding China of $46.1 million, up 6.0% Y/Y • Gross margin at 73.6% vs.
SEC original ↗Staar Surgical CO — Earnings release (8-K exhibit)EX-99May 13, 2026
Net incomequarter
$5.2 million
Net income of $5.2 million or $0.10 per diluted share, compared to a net loss of $(54.2) million or $(1.10) per diluted share a year ago •
SEC original ↗Staar Surgical CO — Earnings release (8-K exhibit)EX-99May 13, 2026
Operating incomequarter
$8.0 million
Operating income for the first quarter of 2026 was $8.0 million compared to an operating loss of $(57.4) million in the prior year quarter.
SEC original ↗Staar Surgical CO — Earnings release (8-K exhibit)EX-99May 13, 2026
Net income for the first quarter of 2026 was $5.2 million or $0.10 per diluted share, up from net loss of $(54.2) million or $(1.10) per diluted share for the prior year quarter.
SEC original ↗Staar Surgical CO — Earnings release (8-K exhibit)EX-99May 13, 2026
Revenuequarter
$1.6 million
Net sales for the December China Shipment were recognized as payments were received, with $1.6 million and $25.9 million of net sales recognized in Q2 FY25 and Q3 FY25, respectively, at 100% gross margin.
SEC original ↗Staar Surgical CO — Earnings release (8-K exhibit)EX-99May 13, 2026
AI analysis
Q1 2026 · reported May 13, 2026
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Headline figures
| Metric | Q1 2026 | Prior qtr | Year ago |
|---|---|---|---|
| Y net income | $5.2 million | — | — |
| EPS | $0.10 | — | — |
| Net revenue | $93.5 million | — | — |
| Growth | up 119.6% | — | — |
| Gross margin | 73.6% | — | — |
| Net income | $5.2 million | — | — |
| Operating income | $8.0 million | — | — |
| Revenue | $1.6 million | — | — |
Guidance · company-stated
No guidance located in the held release
Margin
Capital allocation
The decrease was primarily due to lower advertising and promotional spending and lower trade show expenses, partially offset by an increase in compensation-related expenses and bad debt expense.
The Company has no outstanding debt.
Event summary
Staar Surgical CO Q1 2026 — Y Net Income of $5.2 million, with GAAP EPS of $0.10 Adjusted EBITDA 1 of $24.4 million, or $0.48 per diluted share Earnings Call and Webcast Today at
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
The decrease was primarily due to lower advertising and promotional spending and lower trade show expenses, partially offset by an increase in compensation-related expenses and bad debt expense.
SEC original ↗Staar Surgical CO — Earnings release (8-K exhibit)EX-99May 13, 2026
The Company has no outstanding debt.
SEC original ↗Staar Surgical CO — Earnings release (8-K exhibit)EX-99May 13, 2026
Treasury securities 19,791 1 ( 6 ) 19,786 19,786 Corporate debt securities 2,542 ( 1 ) 2,541 2,541 Total investments AFS $ 32,922 $ 1 $ ( 13 ) $ 32,910 $ 19,786 $ 13,124 January 2, 2026 Fair Value Measurements Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Level 1 Level 2 Commercial paper $ 14,682 $ 1 $ ( 1 ) $ 14,682 $ $ 14,682 Certificates of deposit 816 816 816 U.
SEC original ↗Staar Surgical CO — 10-Q Quarterly report10-QAug 12, 2026
Treasury securities 990 990 990 Corporate debt securities 17,897 3 ( 2 ) 17,898 17,898 Total investments AFS $ 34,385 $ 4 $ ( 3 ) $ 34,386 $ 990 $ 33,396 The Company obtains the fair value from third-party pricing services.
SEC original ↗Staar Surgical CO — 10-Q Quarterly report10-QAug 12, 2026
The Company assessed each debt security in a gross unrealized loss position to determine whether the decline in fair value below amortized cost was a result of credit losses or other factors, whether the Company expects to recover the amortized cost of the debt security, the Company s intent to sell and whether it is more-likely-than-not that the Company will not be required to sell the debt security before the recovery of the amortized cost basis.
SEC original ↗Staar Surgical CO — 10-Q Quarterly report10-QAug 12, 2026
Strategy & priorities
We have made meaningful advancements against our core objectives of Revenue Growth and Profit Expansion, and we expect to advance Product Innovation over the balance of the year.
SEC original ↗Staar Surgical CO — Earnings release (8-K exhibit)EX-99May 13, 2026
net sales growth with quarterly net sales surpassing $6 million • Return to profitability with improving margins 1 Exhibit 99.1 Business Update Our priority in 2026 is to return STAAR to consistent, profitable growth while maintaining disciplined execution.
SEC original ↗Staar Surgical CO — Earnings release (8-K exhibit)EX-99May 13, 2026
Operationally, we are making important advancements across several foundational initiatives.
SEC original ↗Staar Surgical CO — Earnings release (8-K exhibit)EX-99May 13, 2026
China The launch of EVO+ ICL in China represents an important step forward in our innovation strategy.
SEC original ↗Staar Surgical CO — Earnings release (8-K exhibit)EX-99May 13, 2026
EVO+ carries a premium price and is expected to contribute to margin expansion as volumes scale.
SEC original ↗Staar Surgical CO — Earnings release (8-K exhibit)EX-99May 13, 2026
Risks & headwinds
While several headwinds from prior years have eased, we continue to operate in a dynamic global environment shaped by tariffs, geopolitical uncertainty, and uneven macroeconomic conditions.
SEC original ↗Staar Surgical CO — Earnings release (8-K exhibit)EX-99May 13, 2026
We plan for our Nidau facility in 2026 to supply 100% of the EVO ICL and EVO+ ICL lenses we ship to China, without import tariffs.
SEC original ↗Staar Surgical CO — Earnings release (8-K exhibit)EX-99May 13, 2026
Operationally, we have made substantial inroads addressing our most significant challenge from 2025—excess channel inventory.
SEC original ↗Staar Surgical CO — Earnings release (8-K exhibit)EX-99May 13, 2026
Looking ahead, we remain mindful of ongoing macroeconomic uncertainty, including potential impacts of geopolitical disruption on economies in Europe and parts of Asia.
SEC original ↗Staar Surgical CO — Earnings release (8-K exhibit)EX-99May 13, 2026
S 4 Exhibit 99.1 market was partly offset by the macroeconomic and geopolitical headwinds in the Middle East and India markets.
SEC original ↗Staar Surgical CO — Earnings release (8-K exhibit)EX-99May 13, 2026
LEGAL PROCEEDINGS 27 ITEM 1A.
SEC original ↗Staar Surgical CO — 10-Q Quarterly report10-QAug 12, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
32 documents- Q3 2026
- 8-K/ASTAA
Oct 5, 2026
- Q2 2026
- 8-KSTAA
Sep 10, 2026
- 8-KSTAA
Aug 12, 2026
- 10-QSTAA
Aug 12, 2026
- 8-KSTAA
Aug 6, 2026
- Q1 2026
- 8-KSTAA
Jun 22, 2026
- 8-KSTAA
Jun 9, 2026
- 8-KSTAA
May 13, 2026
- 10-QSTAA
May 13, 2026
- 8-KSTAA
Apr 8, 2026
- Q4 2025
- 10-KSTAA
Mar 3, 2026
- 8-KSTAA
Mar 3, 2026
- 8-KSTAA
Feb 5, 2026
- 8-KSTAA
Feb 2, 2026
- EX-99STAA
Feb 2, 2026
- 8-KSTAA
Jan 16, 2026
- 8-KSTAA
Jan 15, 2026
- EX-99STAA
Jan 15, 2026
- 8-KSTAA
Jan 6, 2026
- 8-KSTAA
Jan 6, 2026
- EX-99STAA
Jan 6, 2026
- Q3 2025
- 8-KSTAA
Dec 9, 2025
- 8-KSTAA
Dec 8, 2025
- EX-99STAA
Dec 8, 2025
- 8-KSTAA
Nov 7, 2025
- EX-99STAA
Nov 7, 2025
- 8-KSTAA
Nov 5, 2025
- 10-QSTAA
Nov 5, 2025
- 8-KSTAA
Oct 27, 2025
- EX-99STAA
Oct 27, 2025
- 8-KSTAA
Oct 23, 2025
- EX-99STAA
Oct 23, 2025
Earnings releases
9 documentsPresentations
0 documentsNo presentations for Staar Surgical CO are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Staar Surgical CO are held in this edition of the library.
Mentioned by
1 companyOther tracked companies whose held documents mention Staar Surgical CO by name or ticker. A mention is counted once per document, from the document text the library holds.
“ to helping people see brilliantly, today terminated its definitive merger agreement with STAAR Surgical Company (NASDAQ: STAA) announced on August 5, 2025. “Throughout this …”
See also the earnings calendar for every tracked company’s next earnings date.